Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 1,800 shares, a drop of 84.7% from the October 15th total of 11,800 shares. Based on an average daily volume of 27,600 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Trading Up 0.7 %

Shares of Scinai Immunotherapeutics stock traded up $0.02 during mid-day trading on Wednesday, reaching $3.02. 1,406 shares of the stock were exchanged, compared to its average volume of 311,419. The company has a market cap of $1.75 million, a price-to-earnings ratio of -0.01 and a beta of 2.46. The firm has a 50-day simple moving average of $3.59 and a 200 day simple moving average of $3.79. Scinai Immunotherapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $8.92.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($3.57) earnings per share for the quarter. The business had revenue of $0.28 million for the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.